Strumento inattivo

Altre lingue Hamlet Pharma AB (publ)

Azioni

HAMLET B

SE0015661152

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Hamlet BioPharma Secures Large Scale Alpha1 Peptide Production in an Agreement with Polypeptide Group	18/04
Hamlet BioPharma Announces Commercial Collaborations with Top International Advisory Firms	11/04
Hamlet BioPharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	22/02
Hamlet Biopharma Announces New Analyses of Clinical Data from Alpha1h Treated Patients with Bladder Cancer Detect A Strong Immune Response with Known Anti-Tumor Effects	25/01
Hamlet Biopharma AB Announces Antimicrobial Peptide Therapy for Tuberculosis Infections	20/12
Hamlet Biopharma's Continued Development of Brain Tumor Therapy	06/12
Hamlet BioPharma Receives U.S. FDA Fast Track Designation for Alpha 1H for the Treatment of Non-Muscle Invasive Bladder Cancer	29/11
Hamlet BioPharma AB Reports Earnings Results for the First Quarter Ended September 30, 2023	17/11
Hamlet BioPharma AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2023	28/08/23
Hamlet BioPharma AB Reports Earnings Results for the Full Year Ended June 30, 2023	28/08/23
Hamlet Pharma Announces FDA Clearance of IND Application for Alpha1H for the Treatment of Non-Muscle Invasive Bladder Cancer	01/07/23
Hamlet Pharma Announces CEO Changes	30/06/23
Hamlet Pharma Secures Long-Term Alpha1 Peptide Production in an Agreement with Polypeptide Group	12/06/23
Hamlet Pharma Secures New Alpha1H Production Batch for Continued Clinical Trials	31/05/23
Hamlet Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	26/05/23
Hamlet BioPharma AB (NGM:HAMLET B) completed the acquisition of Selectimmune Pharma AB.	17/05/23
Hamlet Pharma's Bladder Cancer Project Set for EU Commission's Full Funding	14/04/23
Hamlet Pharma to Merge with SelectImmune; Shares Down 10%	31/03/23
Hamlet Pharma and SelectImmune Pharma merge to create an innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections	31/03/23
Hamlet Pharma AB (NGM:HAMLET B) agreed to acquire Selectimmune Pharma AB (NGM:SELECT B).	31/03/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Hamlet Pharma AB (publ)

Azioni

HAMLET B

SE0015661152

Altre lingue

Filtri